ALX Oncology's Evorpacept Combination Data Revealed in ASPEN-07 Trial for Advanced Bladder Cancer Patients
Sunday, 2 June 2024, 11:12
ALX Oncology Evorpacept Combination Data Disclosure
ALX Oncology unveiled the first set of data on combining Evorpacept with an Antibody-Drug Conjugate (ADC) in patients with advanced bladder cancer from the Phase 1 ASPEN-07 clinical trial. This combination therapy showcases promising potential for enhancing treatment outcomes.
Key Highlights:
- Phase 1 ASPEN-07 Clinical Trial Data Revealed
- Evorpacept and ADC Combination
- Initial Results in Advanced Bladder Cancer Patients
This development highlights the ongoing efforts to innovate and advance treatment options for patients with advanced bladder cancer.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.